Key result
Infant and toddler dyslipidemia lacks approved therapies, reserving off-label medications only for severe cases.
Why the study?
Dyslipidemia can present in infancy, but its prevalence and long-term outcomes remain unclear, leaving an unmet need for guidance in evaluation and treatment.
This review provides guidance on the clinical evaluation and management of dyslipidemia in infants and toddlers, emphasizing that while no FDA-approved therapies exist for this age group, nutritional interventions and off-label pharmacological treatments may be considered for severe cases.
Answers are grounded in this paper and cite their sources.
Supports etiology-driven management without approved drugs in infants/toddlers; leaves open need for dedicated pediatric trials.
PURPOSE OF REVIEW: Dyslipidemia can present as early as infancy however the prevalence and long-term outcomes are unclear. There is an unmet need for guidance in the evaluation and treatment approach in these patients. This review summarizes the pathophysiology of dyslipidemia in infants and toddlers and highlights potential treatment options. RECENT FINDINGS: Secondary factors unique to this population including prematurity and reliance on intravenous nutrition play a role in the pathophysiology of dyslipidemia, though primary genetic causes are also recognized. Severe hypertriglyceridemia poses a risk of acute pancreatitis in an already vulnerable population. Persistent dyslipidemia is a concern for future premature cardiovascular disease. Management of dyslipidemia is dependent on its etiology and severity. Primary and secondary causes should be considered and addressed. Although a variety of therapeutic agents are available in older children and adults, no approved therapies exist at this age, though off-label use of medications may be considered.
No takes yet. Share an insight, caveat, or question.
Jennifer C. Kelley (2025) conducted a review in Dyslipidemia. Dyslipidemia in infants and toddlers lacks approved pharmacological therapies, requiring management based on etiology and severity, with off-label medication use considered only in severe cases.
Synapse has enriched 10 related papers. Consider them for comparative context: